Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current topics on cytapheresis technologies.

K Yamaji1, H Tsuda, H Hashimoto

  • 1Department of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan.

Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis
|November 29, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic significance of histologic parameters of soft tissue sarcomas.

Cancer·1992
Same author

A reassessment of histologic classification and an immunohistochemical study of 88 retinoblastomas. A special reference to the advent of bipolar-like cells.

Cancer·1992
Same author

[Elemental analysis of hilar and mediastinal lymph nodes in idiopathic pulmonary fibrosis].

Nihon Kyobu Shikkan Gakkai zasshi·1992
Same author

Relationship between inhibitor of extrathyroidal 5'-deiodinase activity and serum free fatty acid in children with nonthyroidal illness and acute ketosis.

Endocrinologia japonica·1992
Same author

[Changes in seizure-triggering threshold and after discharge duration in seizure susceptibility].

No to shinkei = Brain and nerve·1992
Same author

Mechanism of extracellular ATP-stimulated phosphoinositide hydrolysis in rat glioma C6 cells.

The Journal of pharmacology and experimental therapeutics·1992
Same journal

Apheresis therapy for living-donor liver transplantation: experience for apheresis use for living-donor liver transplantation at Kyoto University.

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
Same journal

Dextran sulfate (Selesorb) plasma apheresis improves vascular changes in systemic lupus erythematosus.

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
Same journal

Improvements in artery occlusion by low-density lipoprotein apheresis in a patient with peripheral arterial disease.

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
Same journal

A case of acute hepatic insufficiency treated with novel plasmapheresis plasma diafiltration for bridge use until liver transplantation.

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
Same journal

A case of nephrotic syndrome due to lupus nephritis which was controlled with low-density lipoprotein apheresis.

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
Same journal

Plasma exchange for hypertriglyceridemic acute necrotizing pancreatitis: report of two cases.

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis·2002
See all related articles

Cytapheresis, including leukocyte and granulocyte apheresis, shows promise for treating autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease by modulating the immune system. The exact mechanism involves cell removal and blood-device interactions, though further research is needed.

Area of Science:

  • Immunology
  • Medical Technology
  • Gastroenterology

Background:

  • Cytapheresis is being explored for autoimmune diseases like rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).
  • Physicians report positive patient responses to cytapheresis for immune disorders.
  • The precise mechanism of cytapheresis in treating immune disorders remains under investigation.

Purpose of the Study:

  • To review current cytapheresis technologies.
  • To elucidate the immunomodulatory mechanisms of cytapheresis for immune disorders.
  • To focus on leukocytapheresis (LCAP) and/or granulocytapheresis (GCAP) for RA and IBD.

Main Methods:

  • Review of existing cytapheresis technologies.
  • Analysis of proposed mechanisms for immune disorder treatment.

Related Experiment Videos

  • Focus on LCAP and GCAP applications in RA and IBD.

    • Main Results:

    • Leukocyte removal (granulocytes, lymphocytes, monocytes) is a key factor in immune system rebalancing.
    • While a single session may not remove sufficient cells, it can trigger immunomodulation.
    • Blood-device interactions during apheresis may also contribute to immunomodulation.

    Conclusions:

    • Cytapheresis, particularly LCAP and GCAP, offers a potential therapeutic strategy for autoimmune diseases.
    • Both direct cell removal and indirect effects from blood-device interactions appear to be involved in its efficacy.
    • Further research is warranted to fully understand and optimize cytapheresis for immune disorders like RA and IBD.